Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
AstraZeneca
Baxter
Johnson and Johnson

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR DIAZOXIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Diazoxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004825 ↗ Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism Completed Children's Hospital of Philadelphia N/A 1998-05-01 OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00004825 ↗ Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism Completed FDA Office of Orphan Products Development N/A 1998-05-01 OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00131755 ↗ Efficacy of Diazoxide in Type 1 Diabetes Completed Grill, Valdemar, M.D. Phase 4 2005-02-01 The purpose of this study is to find out if Diazoxide can partly retain insulin production in newly diagnosed type 1 diabetes patients.
NCT00151684 ↗ Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men Completed Rijnstate Hospital Phase 2 2004-11-01 The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia. Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diazoxide

Condition Name

Condition Name for Diazoxide
Intervention Trials
Hypertriglyceridemia 5
Prader-Willi Syndrome 5
Glucose, High Blood 4
Glucose Metabolism Disorders 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diazoxide
Intervention Trials
Hypoglycemia 7
Hyperinsulinism 7
Syndrome 6
Congenital Hyperinsulinism 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diazoxide

Trials by Country

Trials by Country for Diazoxide
Location Trials
United States 63
United Kingdom 7
Netherlands 3
Canada 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diazoxide
Location Trials
New York 8
California 7
Maryland 4
Colorado 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diazoxide

Clinical Trial Phase

Clinical Trial Phase for Diazoxide
Clinical Trial Phase Trials
Phase 4 6
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diazoxide
Clinical Trial Phase Trials
Completed 21
Withdrawn 5
Suspended 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diazoxide

Sponsor Name

Sponsor Name for Diazoxide
Sponsor Trials
Essentialis, Inc. 8
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5
Albert Einstein College of Medicine 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diazoxide
Sponsor Trials
Other 39
Industry 18
NIH 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Merck
AstraZeneca
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.